New Insights into Alzheimer's Disease : Novel Pathogenesis, Drug Target and Delivery
Alzheimer's disease (AD), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (Aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. However, the developed medicines targeting Aβ and tau have not obtained ideal clinical efficacy, which raises a challenge to the hypothesis that AD is Aβ cascade-induced. A critical problem of AD pathogenesis is which endogenous factor induces Aβ aggregation and tau phosphorylation. Recently, age-associated endogenous formaldehyde has been suggested to be a direct trigger for Aβ- and tau-related pathology. Another key issue is whether or not AD drugs are successfully delivered to the damaged neurons. Both the blood-brain barrier (BBB) and extracellular space (ECS) are the barriers for drug delivery. Unexpectedly, Aβ-related SP deposition in ECS slows down or stops interstitial fluid drainage in AD, which is the direct reason for drug delivery failure. Here, we propose a new pathogenesis and perspectives on the direction of AD drug development and drug delivery: (1) aging-related formaldehyde is a direct trigger for Aβ assembly and tau hyperphosphorylation, and the new target for AD therapy is formaldehyde; (2) nano-packaging and physical therapy may be the promising strategy for increasing BBB permeability and accelerating interstitial fluid drainage.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Pharmaceutics - 15(2023), 4 vom: 03. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chen, Haishu [VerfasserIn] |
---|
Links: |
---|
Themen: |
Alzheimer’s disease |
---|
Anmerkungen: |
Date Revised 01.05.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/pharmaceutics15041133 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356151956 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356151956 | ||
003 | DE-627 | ||
005 | 20231226065844.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/pharmaceutics15041133 |2 doi | |
028 | 5 | 2 | |a pubmed24n1187.xml |
035 | |a (DE-627)NLM356151956 | ||
035 | |a (NLM)37111618 | ||
035 | |a (PII)1133 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chen, Haishu |e verfasserin |4 aut | |
245 | 1 | 0 | |a New Insights into Alzheimer's Disease |b Novel Pathogenesis, Drug Target and Delivery |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.05.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Alzheimer's disease (AD), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (Aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. However, the developed medicines targeting Aβ and tau have not obtained ideal clinical efficacy, which raises a challenge to the hypothesis that AD is Aβ cascade-induced. A critical problem of AD pathogenesis is which endogenous factor induces Aβ aggregation and tau phosphorylation. Recently, age-associated endogenous formaldehyde has been suggested to be a direct trigger for Aβ- and tau-related pathology. Another key issue is whether or not AD drugs are successfully delivered to the damaged neurons. Both the blood-brain barrier (BBB) and extracellular space (ECS) are the barriers for drug delivery. Unexpectedly, Aβ-related SP deposition in ECS slows down or stops interstitial fluid drainage in AD, which is the direct reason for drug delivery failure. Here, we propose a new pathogenesis and perspectives on the direction of AD drug development and drug delivery: (1) aging-related formaldehyde is a direct trigger for Aβ assembly and tau hyperphosphorylation, and the new target for AD therapy is formaldehyde; (2) nano-packaging and physical therapy may be the promising strategy for increasing BBB permeability and accelerating interstitial fluid drainage | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Alzheimer’s disease | |
650 | 4 | |a blood–brain barrier | |
650 | 4 | |a drug delivery | |
650 | 4 | |a extracellular space | |
650 | 4 | |a formaldehyde | |
650 | 4 | |a interstitial fluid | |
700 | 1 | |a Xu, Jinan |e verfasserin |4 aut | |
700 | 1 | |a Xu, Hanyuan |e verfasserin |4 aut | |
700 | 1 | |a Luo, Tiancheng |e verfasserin |4 aut | |
700 | 1 | |a Li, Yihao |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Ke |e verfasserin |4 aut | |
700 | 1 | |a Shentu, Yangping |e verfasserin |4 aut | |
700 | 1 | |a Tong, Zhiqian |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 15(2023), 4 vom: 03. Apr. |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:4 |g day:03 |g month:04 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics15041133 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 4 |b 03 |c 04 |